CXCL9 and ovarian carcinoma: Based on the evidence of human samples and C57BL/6 mouse assay, hyper-expressed CXCL9 has been proven to stifle tumor cell growth and promote anti-PD-L1 therapy in ovarian cancer, especially the histological subtypes of clear-cell carcinomas (23).